Three Cases of Reversible Agranulocytosis after Treatment with Lamotrigine by Ahn, Yong Min et al.
 
 
 
 
online © ML Comm  
www.psychiatryinvestigation.org 121 
0CASE REPORT0 
Print  ISSN 1738-3684 / On-line  ISSN 1976-3026
Copyright ⓒ 2008 Official Journal of Korean Neuropsychiatric Association
Psychiatry Invest 2008;5:121-123 
 
Three Cases of Reversible Agranulocytosis after 
Treatment with Lamotrigine 
 
 
 
Several psychotropic drugs, including clozapine, are known to cause agranulocytosis and 
this may lead to a fatal condition. Lamotrigine is an anticonvulsant that the Food and Drug 
Administration (FDA) has approved for the depression of bipolar disorder. A few cases of 
lamotrigine-induced agranulocytosis have been previously reported on, but the pathophys-
iology and clinical manifestations are not yet known. This case series reports on 3 patients 
with different medical conditions who experienced agranulocytosis during treatment with 
lamotrigine. In these cases, the agranulocytosis occurred a few weeks after initiation of 
lamotrigine and it rapidly disappeared after discontinuation. We also discuss several charac-
teristics of lamotrigine-induced agranulocytosis. 
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Introduction 
 
Lamotrigine is ananticonvulsant that the Food and Drug Administration (FDA)
has approved for the depression of bipolar disorder. Though skin rashes are the most 
well known side effect of lamotrigine, blood dyscrasias such as neutropenia, throm-
bocytopenia and pancytopenia have also been reported.
1 Furthermore, a few cases of 
lamotrigine-induced agranulocytosis have been reported,
2-5 but its exact pathophys-
iology is as yet unknown.
6 It has been reported that half of the patients with bipolar 
disorder may take at least 3 psychotropic drugs,
7 and that the usage of multiple drugs 
increases the risk of agranulocytosis.
8 Therefore, it is necessary to be aware of the 
possibility of agranulocytosis during the treatment of bipolar disorder with lamotri-
gine.
7 We report here on 3 cases of agranulocytosis with their different character-
istics during treatment with lamotrigine. 
 
Cases 
 
Case 1 
A 20-year-old man was admitted to a psychiatric ward due to depressive mood of bi-
polar I disorder. The WBC count and absolute neutrophil count (ANC) at the time of ad-
mission were 4,400 cells/mm
3 and 2240 cells/mm
3, respectively. 
On day 2, treatment with lamotrigine (12.5 mg/day) and amisulpiride was ini-
tiated and the lamotrigine was increased to 75 mg/day after 4 weeks with 200 mg of 
amisulpiride. Fluoxetine was prescribed at week 5, along with increasing the dose of
lamotrigine to 100 mg/day by week 6. 
 A CBC at the 45
th day after starting the lamotrigine revealed a WBC count of 2,390
cells/mm
3 and an ANC count of 574 cells/mm
3. The lamotrigine was discontinued im-
mediately, while the other concurrent drugs were maintained. At the next day, a
CBC revealed an ANC count of 380 cells/mm
3 with agranulocytosis. Although there 
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were no signs of infection, we injected 30 μg of G-CSF 
and filgrastim, after consulting a hematologist. An ANC 
count on the 6
th day after lamotrigine discontinuation was 
3,503 cells/mm
3 with a normal WBC count (Figure 1).  
 
Case 2 
A 19-year-old woman was treated for bipolar II dis-
order with quetiapine, paroxetine, trazodone, and valproic 
acid for about 6 months before admission. During this 
period, she presented with mild neutropenia (ANC count: 
1000-1500 cells/mm
3), and the cause of this was assu-
med to be the valproic acid. After the valproic acid was 
discontinued about 3 months before admission, her ANC 
count  was  normalized.    
Due to the aggravation of her suicidal ideation, she was 
admitted and then started on 25 mg of lamotrigine. A CBC 
done at the time of admission showed a WBC count of 
4,900 cells/mm
3 and an ANC count of 2,328 cells/mm
3. 
Neutropenia manifested on day 14 (an ANC count of 
1,282 cells/mm
3), but upon consultation with a hemato-
logist, the lamotrigine prescription was continued upon 
consideration of her previous history of persistent neutro-
penia. On day 24, her ANC count was reduced to 720 
cells/mm
3, so on day 26, the dosage of lamotrigine was 
reduced to 12.5 mg/day. But on day 27 there was an 
outbreak of agranulocytosis (ANC count: 491 cells/mm
3), 
and the lamotrigine was discontinued immediately (con-
current medications: 5 mg of olanzapine, 200 mg of qu-
etiapine and 50 mg of trazodone) (Figure 1). On the 7
th 
day after lamotrigine discontinuation, her ANC count 
(2,330 cells/mm
3) was normalized (Figure 1). 
Due to her severe suicidal ideation, clozapine was 
initiated about 33 days later and the lamotrigine was re-
introduced approximately 100 days after its discontinua-
tion. Now, about 27 months later, she is on 300 mg of 
lamotrigine and 262.5 mg of clozapine without any he-
matologic abnormalities. 
 
Case 3 
A 27-year-old man had been taking risperidone for 6 
years for the treatment of bipolar I disorder. He was 
admitted due to a depressive mood and auditory halluci-
nations. A CBC done on admission day showed a WBC 
count of 12,670 cells/mm
3 and an ANC count of 9,541 
cells/mm
3. The patient was started on lamotrigine (25 
mg/day) and this was increased to 100 mg/day 18 days 
later. On the 20
th day, 12.5 mg of clozapine was added 
and a CBC revealed a WBC count of 6,510 cells/mm
3 
and an ANC count of 3,431 cells/mm
3. 
On the 29
th day after lamotrigine initiation (the 9
th 
day after clozapine initiation), a CBC revealed an ANC 
count of 348 cells/mm
3 with agranulocytosis (concur-
rent medication: 4 mg of risperidone and 175 mg of clo-
zapine). The lamotrigine was discontinued immediately. 
On the 3
rd day after discontinuation, the patient’s ANC 
count increased to 2,367 cells/mm
3 (Figure 1). After-
wards, the risperidone was discontinued, and the dosage 
of clozapine was increased to 225 mg, and there have 
not been any hematologic abnormalities since then. 
 
Discussion  
 
In case 1 and 2, although the other concurrently ad-
ministered drugs could not be definitely excluded from 
the possibility of inducing agranulocytosis,
8 it is rela-
tively easy to consider lamotrigine as the cause of agran-
ulocytosis because the patients had been taking other 
drugs for over 6 months without any hematologic abnor-
malities. In case 3, though it was difficult to make the 
proper clinical judgment, lamotrigine was supposed to 
be the cause of agranulocytosis because clozapine had 
been taken only for 9 days, which is too short a time to 
cause agranulocytosis.
9  
In these 3 cases, agranulocytosis occurred on days 46, 
27 and 29 after lamotrigine initiation, respectively, and 
in the 3 previously reported cases,
2-4 the agranulocytosis 
also occurred within 8 weeks. It is likely that lamotrigine-
induced agranulocytosis has a tendency to occur at the 
early phase of treatment, which is unlike clozapine that 
rarely induces agranulocytosis within the first 6 weeks.
9 
In cases 1 and 3, the agranulocytosis occurred 4 days 
after an increased titration of lamotrigine. In the 3 pre-
viously reported cases, the durations between an increa-
sed dose of lamotrigine and the hematologic abnormal-
ities were also 3-4 days.
2,10,11 For our cases, the doses 
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FIGURE 1. Changes of the absolute neutrophil counts after treat-
ment with lamotrigine. 
Days since the start of lamotrigine administration  
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of lamotrigine at the onset of agranulocytosis were 100 
mg, 25 mg and 150 mg, respectively, and in the previous 
reports, the doses of lamotrigine ranged from 50 mg to 
250 mg. These findings may suggest that the increased 
titration is more important for inducing agranulocytosis 
rather than the dosage itself. 
There was one previous case report in which lamotri-
gine was restarted after neutropenia.
10 They reported that 
the neutropenia reappeared within 2 days when lamotri-
gine was restarted after 17 days. But in our case 2, lamotri-
gine was restarted about 100 days after its discontinuation 
and there have been no other hematologic abnormalities. 
Like clozapine,
12 more experience and data should be ac-
cumulated to understand these differences.   
In our cases, the patients’ hematologic abnormalities 
were normalized within 1 week after lamotrigine dis-
continuation, which corresponds with the previous case 
reports. Since fast recovery is unusual for the cases of 
clozapine-induced agranulocytosis, lamotrigine-induced 
agranulocytosis may have a different mechanism for in-
ducing agranulocytosis. 
To conclude, at the early phase of lamotrigine treat-
ment or after an increased titration of lamotrigine, it is 
beneficial for the clinician to aware the possibility of an 
occurrence of agranulocytosis, although it is very rare 
and this condition was reversible in our cases.   
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